Ascletis Pharma: Invalidation of Gilead Patents Won't Help
China's State Intellectual Property Office (SIPO) last week invalidated Gilead Sciences (GILD US) 's patent claims on the base compound for...
919 Views
Last Week in GER Research: Tesla, Pinduoduo, Beigene, Koolearn, Pintec, STX and China Tower
Below is a recap of the key research produced by the Global Equity Research team. This week we highlight some detailed math on a potential Tesla...
454 Views
BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis
Hong Kong investors have had their first taste of biotech stocks with the recent listings of Ascletis Pharma Inc (1672 HK) and BeiGene Ltd (6160...
549 Views
ECM Coverage Weekly Update (11 August 2018)
Aequitas Research puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. It has been a fairly quiet...
644 Views
BeiGene (百济神州) Post-IPO: An ADR Tracker with Limited Near-Term Upside
BeiGene is the second biotech company to list in Hong Kong under amended listing rules that allow biotech companies which are yet to see a profit...
535 Views